Hill-Rom Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Hill-Rom stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HRC, but not buy additional shares or sell existing shares.
View analyst ratings for Hill-Rom or view top-rated stocks.

Wall Street analysts have given Hill-Rom a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hill-Rom wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Hill-Rom saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 765,700 shares, a decrease of 20.0% from the August 15th total of 957,400 shares. Based on an average daily trading volume, of 822,000 shares, the short-interest ratio is presently 0.9 days. Currently, 1.2% of the company's shares are short sold.
View Hill-Rom's Short Interest.

Hill-Rom is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Hill-Rom.

Hill-Rom Holdings, Inc. (NYSE:HRC) posted its earnings results on Friday, July, 30th. The medical technology company reported $1.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.35 by $0.03. The medical technology company earned $717.70 million during the quarter, compared to analysts' expectations of $708.33 million. Hill-Rom had a net margin of 8.12% and a trailing twelve-month return on equity of 21.74%. The firm's quarterly revenue was down 6.5% on a year-over-year basis. During the same quarter last year, the company earned $1.95 EPS.
View Hill-Rom's earnings history.

Hill-Rom's stock was trading at $89.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HRC stock has increased by 68.8% and is now trading at $150.50.
View which stocks have been most impacted by COVID-19.

Hill-Rom announced a quarterly dividend on Thursday, July 8th. Stockholders of record on Friday, September 17th will be paid a dividend of $0.24 per share on Thursday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, September 16th.
View Hill-Rom's dividend history.

Hill-Rom pays an annual dividend of $0.96 per share and currently has a dividend yield of 0.64%. Hill-Rom does not yet have a strong track record of dividend growth. The dividend payout ratio of Hill-Rom is 17.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Hill-Rom will have a dividend payout ratio of 14.98% next year. This indicates that Hill-Rom will be able to sustain or increase its dividend.
View Hill-Rom's dividend history.

Hill-Rom issued an update on its FY 2021 earnings guidance on Friday, August, 6th. The company provided earnings per share (EPS) guidance of $6.080-$6.120 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.060. The company issued revenue guidance of $2.97 billion-$3.00 billion, compared to the consensus revenue estimate of $2.94 billion.

6 analysts have issued 12 month target prices for Hill-Rom's shares. Their forecasts range from $117.00 to $156.00. On average, they anticipate Hill-Rom's stock price to reach $136.33 in the next twelve months. This suggests that the stock has a possible downside of 9.4%.
View analysts' price targets for Hill-Rom or view top-rated stocks among Wall Street analysts.

54 employees have rated Hill-Rom CEO John P. Groetelaars on Glassdoor.com. John P. Groetelaars has an approval rating of 82% among Hill-Rom's employees.

Some companies that are related to Hill-Rom include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of HRC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), The Walt Disney (DIS), NVIDIA (NVDA), Square (SQ), PayPal (PYPL), salesforce.com (CRM), CVS Health (CVS), Micron Technology (MU), AbbVie (ABBV) and Bank of America (BAC).

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Hill-Rom's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.20%), BlackRock Inc. (9.68%), Victory Capital Management Inc. (5.49%), UBS Asset Management Americas Inc. (2.94%), State Street Corp (2.70%) and Cooke & Bieler LP (2.69%). Company insiders that own Hill-Rom stock include Amy M Dodrill, Andreas G Frank, Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone and Paul Sherwood Johnson.
View institutional ownership trends for Hill-Rom.

HRC stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., UBS Asset Management Americas Inc., BlackRock Inc., Natixis, LSV Asset Management, FMR LLC, Invesco Ltd., and Dimensional Fund Advisors LP. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone, and Paul Sherwood Johnson.
View insider buying and selling activity for Hill-Rom or view top insider-selling stocks.

HRC stock was bought by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Balyasny Asset Management LLC, Cooke & Bieler LP, Victory Capital Management Inc., Allianz Asset Management GmbH, Northern Trust Corp, Amundi, and Goldman Sachs Group Inc..
View insider buying and selling activity for Hill-Rom or or view top insider-buying stocks.

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HRC stock can currently be purchased for approximately $150.50.

Hill-Rom has a market capitalization of $9.91 billion and generates $2.88 billion in revenue each year. The medical technology company earns $223 million in net income (profit) each year or $5.53 on an earnings per share basis.

Hill-Rom employs 10,000 workers across the globe.

The official website for Hill-Rom is www.hill-rom.com.

Hill-Rom is headquartered at 130 East Randolph Street Suite 1000, Chicago IL, 60601.

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at (312) 819-7200 or via email at [email protected]